<?xml version="1.0" encoding="UTF-8"?>
<list>
  <sentences>
    <s path="[OANC]/data/written_2/technical/biomed/1471-213X-1-15.anc" start="22471" end="22476" sStart="22344" offset="127" sid="r7.1.use.v.0714" wn="1" wnkey="use%2:34:01::" annotator="jeneale" text="Thus, we determined if SN50 treatment was associated with activation of the ERK1/2 and Caspase 3 pathways, using E15 + 2 control and SN50-treated explants, 1-D Western blot analysis, and antibodies specific to activated (phosphorylated/cleaved) proteins." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-213X-1-15.anc" start="8583" end="8588" sStart="null" offset="140" sid="r7.1.use.v.0508" wn="1" wnkey="use%2:34:01::" annotator="cgozo" text="To investigate transcriptional responses to NF-?B inhibition, we analyzed control and SN50-treated E15 + 2 SMG explants using cDNA arrays." />
    <s path="file:/D:/Corpora/oanc/data/written_2/technical/biomed/1471-213X-1-15.anc" start="42257" end="42268" sStart="null" offset="0" sid="null" wn="3" wnkey="transfer%2:38:05::" annotator="tofox" text="Each sample (CONT and SN50-treated) was analyzed on 4 separate 2-D gels which were then &lt;b&gt;transferred&lt;/b&gt; onto 4 blots." />
    <s path="file:/c:/OANC/data/written_2/technical/biomed/1471-213X-1-15.anc" start="25394" end="25399" sStart="null" offset="0" sid="null" wn="2" wnkey="show%2:31:00::" annotator="carichter" text="Finally, it should be noted that a recent study using cell lines raised the possibility that SN50's action is not specific to NF-?B [ 61 62 ] . SN50 is composed of the NLS for NF-?B p50 and was believed to specifically block NF-?B p50/p65 nuclear translocation by binding the NLS receptor complex and preventing transport through the nuclear pore [ 33 34 35 ] . However, Torgerson and coworkers [ 61 ] have &lt;b&gt;shown&lt;/b&gt; that SN50 treatment inhibited nuclear transport of transcription factors NFAT, AP-1, STAT1, and NF-?B at a high dose of 210 ?g/ml in Junkrat cells." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-213X-1-15.anc" start="2281" end="2286" sStart="null" offset="173" sid="r9.sense.n.0175" wn="2" wnkey="sense%1:10:00::" annotator="cgozo" text="This requires the integration of transcriptomic, proteomic, phenomic, and bioinformatic approaches, not least because development, in its most basic sense, is genes plus context [ 19 20 21 22 ] ." />
    <s path="file:/D:/Corpora/oanc/data/written_2/technical/biomed/1471-213X-1-15.anc" start="2942" end="2947" sStart="null" offset="0" sid="null" wn="1" wnkey="rapid%5:00:00:fast:01" annotator="veweser" text="Exposure of cells to stimuli of NF-?B induces the &lt;b&gt;rapid&lt;/b&gt; phosphorylation and subsequent degradation of I?B proteins." />
    <s path="file:/D:/Corpora/oanc/data/written_2/technical/biomed/1471-213X-1-15.anc" start="2942" end="2947" sStart="null" offset="0" sid="null" wn="1" wnkey="rapid%5:00:00:fast:01" annotator="carichter" text="Exposure of cells to stimuli of NF-?B induces the &lt;b&gt;rapid&lt;/b&gt; phosphorylation and subsequent degradation of I?B proteins." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-213X-1-15.anc" start="15026" end="15030" sStart="null" offset="278" sid="r7.poor.j.0832" wn="5" wnkey="poor%5:00:00:insufficient:00" annotator="cgozo" text="However, one cannot extrapolate from mRNA abundance to relevant protein levels [ 48 ] . A recent study by Aebersole and coworkers [ 48 ] analyzing yeast protein and mRNA abundance clearly showed that mRNA transcript levels are poor predictors of protein expression." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-213X-1-15.anc" start="11165" end="11169" sStart="null" offset="137" sid="r7.poor.j.0299" wn="4" wnkey="poor%3:00:02::" annotator="brubin" text="Although many &quot;Ras/Raf&quot; growth factor pathway transcripts were upregulated (Table 1), as a group they were poor predictors of SMG phenotype (control v." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-213X-1-15.anc" start="18137" end="18147" sStart="null" offset="3" sid="r10.particular.j.0691" wn="3" wnkey="particular%5:00:00:uncommon:00" annotator="cgozo" text="Of particular note are c-Raf, ERK2, and JAK1." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-213X-1-15.anc" start="30523" end="30527" sStart="null" offset="329" sid="r8.life.n.0740" wn="2147483645" wnkey="null" annotator="cgozo" text="E15 SMG (mostly Canalicular Stage) primordia were cultured using a modified Trowell method as previously described [ 13 ] . The medium consisted of BGJb (Life Technologies, Rockville, MD) supplemented with 0.5 mg ascorbic acid/ml and 50 units penicillin/streptomycin (Life Technologies), pH 7.2, and replicate cultures were changed every other day." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-213X-1-15.anc" start="22691" end="22697" sStart="null" offset="31" sid="r9.level.n.0789" wn="1" wnkey="level%1:07:00::" annotator="veweser" text="Specifically, we evaluated the levels of activated c-Raf, ERK1/2, Caspase 3, and PARP using antibodies which identify only the phosphorylated or cleaved proteins and do not cross react with the inactive protein." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-213X-1-15.anc" start="42621" end="42626" sStart="null" offset="90" sid="r9.level.n.0591" wn="1" wnkey="level%1:07:00::" annotator="cgozo" text="For this set of experiments, two independent samples were analyzed The relative level of proteins were determined by phosphor imaging and normalized to overall signal." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-213X-1-15.anc" start="41895" end="41901" sStart="null" offset="210" sid="r9.level.n.0128" wn="2" wnkey="level%1:26:01::" annotator="brubin" text="Using highly specific monoclonal antibodies in antibody combinations carefully formulated by BD Transduction Laboratories, this multiprotein assay detects proteins to the nanogram levels and can distinguish closely related members of many important signaling families." />
    <s path="file:/D:/Corpora/oanc/data/written_2/technical/biomed/1471-213X-1-15.anc" start="40188" end="40194" sStart="null" offset="0" sid="null" wn="3" wnkey="image%1:06:00::" annotator="veweser" text="We generated pseudocolored &lt;b&gt;images&lt;/b&gt; indicating up and down gene regulation." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-213X-1-15.anc" start="20890" end="20898" sStart="null" offset="135" sid="r11.function.n.0448" wn="3" wnkey="function%1:04:00::" annotator="vebatchelder" text="This proteomic analysis is a time-based &quot;snapshot&quot; of proteins assumed to be associated with physiologic function at the moment of SMG harvesting." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-213X-1-15.anc" start="44740" end="44744" sStart="null" offset="44" sid="r9.fold.v.0857" wn="2147483645" wnkey="null" annotator="veweser" text="The SN50 results are presented as fold change relative to CONT protein." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-213X-1-15.anc" start="19735" end="19739" sStart="null" offset="54" sid="r9.fold.v.0581" wn="2147483645" wnkey="null" annotator="veweser" text="By E18, SMG CORT has increased more than 50-fold, and SMG GR has increased nearly 11-fold." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-213X-1-15.anc" start="23834" end="23838" sStart="null" offset="26" sid="r9.fold.v.0577" wn="2147483645" wnkey="null" annotator="veweser" text="13) associated with a 1.5-fold increase in total ERK2 protein (Table 2)." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-213X-1-15.anc" start="5861" end="5865" sStart="null" offset="35" sid="r9.fold.v.0517" wn="2147483645" wnkey="null" annotator="veweser" text="4A) and a significant 10-fold increase (t 4 = 7.98; p &lt; 0.001) in apoptosis (Fig." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-213X-1-15.anc" start="15735" end="15739" sStart="null" offset="73" sid="r9.fold.v.0783" wn="2147483645" wnkey="null" annotator="cgozo" text="As shown in Table 2, we find 18 proteins which have both a 1.5-fold or greater change with NF-?B inhibition and are specifically related to the" />
    <s path="[OANC]/data/written_2/technical/biomed/1471-213X-1-15.anc" start="24651" end="24655" sStart="null" offset="295" sid="r9.fold.v.0751" wn="2147483645" wnkey="null" annotator="cgozo" text="The latter is consistent with the demonstration that c-Raf function is not mediated by the MAPK/ERK cascade [ 59 ] . Moreover, although we find an increase in total Raf protein (Table 2), no increase in activated c-Raf is found; we also see a 2-fold increase in activated Caspase 3 but no change in total Caspase 3 protein." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-213X-1-15.anc" start="23284" end="23288" sStart="null" offset="102" sid="r9.fold.v.0587" wn="2147483645" wnkey="null" annotator="cgozo" text="The greater than 2-fold increase in Caspase 3 activation is associated with a 1.8-fold increase in PARP cleavage (Fig." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-213X-1-15.anc" start="24179" end="24183" sStart="null" offset="73" sid="r9.fold.v.0920" wn="2147483645" wnkey="null" annotator="brubin" text="Paradoxically, increased ERK1 activation is seen despite a 1.6-fold decrease in total ERK1 protein (Table 2) and increased ERK 1/2 activation is associated with virtually no change in the antecedent activation of c-Raf." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-213X-1-15.anc" start="23737" end="23741" sStart="null" offset="66" sid="r9.fold.v.0716" wn="2147483645" wnkey="null" annotator="brubin" text="Regarding the ERK1/2 pathway, we found a greater than 2-fold increase of activated ERK2 in SN50-treated glands (Fig." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-213X-1-15.anc" start="23344" end="23348" sStart="null" offset="23" sid="r9.fold.v.0576" wn="2147483645" wnkey="null" annotator="brubin" text="14) and a 10-fold increase in apoptosis (Fig." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-213X-1-15.anc" start="18797" end="18801" sStart="null" offset="66" sid="r9.fold.v.0124" wn="2147483645" wnkey="null" annotator="brubin" text="Moreover, it is especially noteworthy that the nearly 2-fold decline of glucocorticoid receptor (GR) (Table 2) is also of very high relative importance in defining SMGs deprived of NF-?B nuclear translocation." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-213X-1-15.anc" start="15297" end="15301" sStart="null" offset="222" sid="r9.fold.v.0722" wn="" wnkey="null" annotator="anfahmy" text="They demonstrate that some genes with comparable mRNA levels exhibited a 20-fold difference in their protein expression while mRNA levels of comparable protein expression varied as much as 30-fold." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-213X-1-15.anc" start="40542" end="40551" sStart="null" offset="36" sid="r8.1.different.j.0067" wn="5" wnkey="different%5:00:01:other:00" annotator="veweser" text="Total signal intensity of different probes was scaled to the same value before comparison." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-213X-1-15.anc" start="40542" end="40551" sStart="null" offset="36" sid="r8.1.different.j.0067" wn="1" wnkey="different%3:00:00::" annotator="jeneale" text="Total signal intensity of different probes was scaled to the same value before comparison." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-213X-1-15.anc" start="40542" end="40551" sStart="null" offset="36" sid="r8.1.different.j.0067" wn="1" wnkey="different%3:00:00::" annotator="cgozo" text="Total signal intensity of different probes was scaled to the same value before comparison." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-213X-1-15.anc" start="10971" end="10980" sStart="null" offset="60" sid="r8.1.different.j.0703" wn="1" wnkey="different%3:00:00::" annotator="brubin" text="Contemporaneous proteome analysis provides a very different profile (see Table 2and text below)." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-213X-1-15.anc" start="40542" end="40551" sStart="null" offset="36" sid="r8.1.different.j.0067" wn="1" wnkey="different%3:00:00::" annotator="brubin" text="Total signal intensity of different probes was scaled to the same value before comparison." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-213X-1-15.anc" start="35344" end="35348" sStart="null" offset="126" sid="r11.dark.j.0406" wn="2" wnkey="dark%3:00:02::" annotator="vebatchelder" text="In this set of experiments, the cytoplasm appears blue and activated p53-positive cells appear dark brown." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-213X-1-15.anc" start="38238" end="38242" sStart="null" offset="27" sid="r11.dark.j.0407" wn="2" wnkey="dark%3:00:02::" annotator="anfahmy" text="Apoptotic nuclei appear as dark brown." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-213X-1-15.anc" start="36152" end="36156" sStart="null" offset="342" sid="r11.dark.j.0095" wn="2" wnkey="dark%3:00:02::" annotator="anfahmy" text="E15 + 2 CONT or SN50-treated explants were sectioned, incubated with anti-PCNA using the Zymed mouse PCNA kit (South San Francisco, CA), and counterstained with hematoxylin as previously described [ 13 ] . In this set of experiments, the cytoplasm appears blue and PCNA-positive cells appear dark brown." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-213X-1-15.anc" start="38452" end="38456" sStart="null" offset="34" sid="r11.dark.j.0408" wn="2" wnkey="dark%3:00:02::" annotator="adelpriore" text="Only apoptotic (variously intense dark brown) nuclei were counted in control and SN50-treated sections." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-213X-1-15.anc" start="36152" end="36156" sStart="null" offset="342" sid="r11.dark.j.0095" wn="2" wnkey="dark%3:00:02::" annotator="adelpriore" text="E15 + 2 CONT or SN50-treated explants were sectioned, incubated with anti-PCNA using the Zymed mouse PCNA kit (South San Francisco, CA), and counterstained with hematoxylin as previously described [ 13 ] . In this set of experiments, the cytoplasm appears blue and PCNA-positive cells appear dark brown." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-213X-1-15.anc" start="11345" end="11352" sStart="null" offset="91" sid="r10.control.n.0849" wn="4" wnkey="control%1:09:02::" annotator="veweser" text="9A) shows that only IGF2, IGF2R, and IGFBP3 are best at discriminating control from SN50-treated explants." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-213X-1-15.anc" start="6683" end="6690" sStart="null" offset="60" sid="r10.control.n.0131" wn="4" wnkey="control%1:09:02::" annotator="cgozo" text="As expected, we found a marked difference between control and SN50-treated SMGs but none between control and mutant peptide-treated explants (data not shown)." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-213X-1-15.anc" start="31288" end="31295" sStart="null" offset="566" sid="r10.control.n.0972" wn="4" wnkey="control%1:09:02::" annotator="brubin" text="In each of the enumerated studies, a minimum of 12 explants were cultured for 2 or 4 days in the cell permeable peptide SN50 (Biomol Research, Plymouth Meeting, PA) which inhibits NF-?B translocation into the nucleus [ 24 33 34 35 ] . The concentration used (100 ?g/ml) was double that shown to inhibit NF-?B translocation in mouse endothelial LE-II cells; 100 ?g/ml mutant SN50 (mSN50) peptide was used as a positive control and control BGJb medium as a negative control." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-213X-1-15.anc" start="23147" end="23154" sStart="null" offset="89" sid="r10.control.n.0704" wn="4" wnkey="control%1:09:02::" annotator="brubin" text="14); no change was seen in activated c-Raf levels between control and SN50-treated explants." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-213X-1-15.anc" start="7238" end="7245" sStart="null" offset="22" sid="r10.control.n.0458" wn="4" wnkey="control%1:09:02::" annotator="anfahmy" text="Thus, we cultured E15 control, SN50-treated, and mSN50-treated explants in the presence of TNF (rTNF, 10 U/ml) supplementation for 4 or more days." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-213X-1-15.anc" start="41751" end="41763" sStart="null" offset="66" sid="r11.combination.n.0878" wn="1" wnkey="combination%1:14:00::" annotator="anfahmy" text="Using highly specific monoclonal antibodies in antibody combinations carefully formulated by BD Transduction Laboratories, this multiprotein assay detects proteins to the nanogram levels and can distinguish closely related members of many important signaling families." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-213X-1-15.anc" start="38384" end="38391" sStart="null" offset="134" sid="r9.appear.v.0757" wn="1" wnkey="appear%2:39:00::" annotator="veweser" text="Since the sections were not counterstained with hematoxylin in this set of experiments, epithelial cell cytoplasm appears as light brown." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-213X-1-15.anc" start="36145" end="36151" sStart="null" offset="335" sid="r9.appear.v.0509" wn="1" wnkey="appear%2:39:00::" annotator="veweser" text="E15 + 2 CONT or SN50-treated explants were sectioned, incubated with anti-PCNA using the Zymed mouse PCNA kit (South San Francisco, CA), and counterstained with hematoxylin as previously described [ 13 ] . In this set of experiments, the cytoplasm appears blue and PCNA-positive cells appear dark brown." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-213X-1-15.anc" start="38228" end="38234" sStart="null" offset="17" sid="r9.appear.v.0650" wn="5" wnkey="appear%2:30:02::" annotator="anfahmy" text="Apoptotic nuclei appear as dark brown." />
  </sentences>
</list>